Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen Achieves Merus Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

ProBioGen Achieves Merus Milestone

Phase I trial will leverage GlymaxX cancer cell-killing enhancement antibody technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG has achieved an undisclosed milestone payment from Merus N.V. based on Merus’ use of MCLA-158, a bispecific antibody using the GlymaxX antibody-dependent cell-mediated cytotoxicity (ADCC)-enhancing technology in its Phase I trial. The trial in patients with solid tumors will initially focus on metastatic colorectal cancer. MCLA-158 uses ProBioGen’s GlymaxX technology for greater cell-killing potential. GlymaxX is a stable modification, applicable to any producer cell, leading them to produce antibodies without the sugar fucose. GlymaxX-modified afucosylated antibodies recruit and activate immune effector cells more effectively with a much higher tumor cell killing activity, potentially requiring much lower doses with less side effects.
 
Merus and ProBioGen entered an agreement in 2016 for the use of the GlymaxX ADCC enhancement technology in MCLA-158. Under the terms, Merus obtained non-exclusive rights to use the GlymaxX technology for Merus’ Bioclonics pipeline of bispecific antibodies designed to treat various forms of cancer to enhance their ADCC activity.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics